0000000001259998

AUTHOR

Piercarlo Sarzi-puttini

showing 26 related works from this author

CC chemokine receptor 5 polymorphism in Italian patients with Beḩet's disease

2012

OBJECTIVE: To evaluate the potential role of CC chemokine receptor 5 (CCR5)Δ32 polymorphism in the susceptibility to and clinical expression of Behcet's disease (BD) in a cohort of Italian patients. METHODS: One hundred and ninety-six consecutive Italian patients satisfying the ISG criteria for BD were followed up for 8 years, and 180 healthy age- and sex-matched blood donors were molecularly genotyped for the CCR5Δ32 polymorphism. A standard microlymphocytotoxicity technique was used to serotype HLA-B51. The patients were subgrouped on the basis of the presence or absence of clinical manifestations. RESULTS: The distribution of the CCR5Δ32 genotype differed between BD patients and controls…

AdultMalemedicine.medical_specialtyHeterozygoteReceptors CCR5Behcet's disease CCR5 polymorphismBehcet's diseaseGastroenterologyRheumatologyGeneticGene FrequencyInternal medicineGenotypeReceptorsMedicineHumansPharmacology (medical)Genetic Predisposition to DiseaseAllelePolymorphismAllele frequencyPolymorphism Geneticbusiness.industryBehcet SyndromeHomozygoteCase-control studyOdds ratiomedicine.diseaseBeḩet's disease; CC chemokine receptor 5 Δ32 olymorphism; Chemokines; Disease manifestations; Adult; Behcet Syndrome; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to Disease; HLA-B Antigens; Heterozygote; Homozygote; Humans; Italy; Male; Polymorphism Genetic; Receptors CCR5; Rheumatology; Pharmacology (medical)Adult; Behcet Syndrome; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to Disease; HLA-B Antigens; Heterozygote; Homozygote; Humans; Italy; Male; Polymorphism Genetic; Receptors CCR5ItalyHLA-B AntigensCase-Control StudiesImmunologyCohortFemalebusinessCC chemokine receptorsCCR5
researchProduct

Fibromyalgia and arthritides

2012

Fibromyalgia (FM) is a chronic pain syndrome that affects at least 2% of the adult population. It is characterised by widespread pain, fatigue, sleep alterations and distress, and emerging evidence suggests a central nervous system (CNS) malfunction that increases pain transmission and perception. FM is often associated with other diseases that act as confounding and aggravating factors, such as rheumatoid arthritis (RA), spondyloarthritides (SpA), osteoarthritis (OA) and thyroid disease. Mechanism-based FM management should consider both peripheral and central pain, including effects due to cerebral input and that come from the descending inhibitory pathways. Rheumatologists should be able…

medicine.medical_specialtylcsh:Internal medicineCentral nervous systemlcsh:MedicineOsteoarthritisSeverity of Illness IndexArthritis RheumatoidDiagnosis DifferentialRheumatologyQuality of lifeFibromyalgiaOsteoarthritisSpondylarthritismedicineHumanspainAggravating Factorlcsh:RC31-1245FatiguePain Measurementbusiness.industryArthritisThyroid diseaselcsh:Rmedicine.diseaseThyroid DiseasesArthritides pain fibromyalgia rheumatic diseasesarthritidesDistressmedicine.anatomical_structurearthritides; fibromyalgia; pain; rheumatic diseasesRheumatoid arthritisPhysical therapyrheumatic diseasesfibromyalgiaChronic Painbusiness
researchProduct

Different effects of biological drugs in rheumatoid arthritis

2013

Biological drugs have brought new hope to patients with rheumatoid arthritis (RA) in whom previously existing treatments could not control inflammation, joint destruction, or the progression of disability. The five currently available TNF blockers are approved for treating RA patients, but they have different structures, morphology, pharmacokinetic properties, and activity. Randomised clinical trials (RCTs) have shown that they improve the signs and symptoms of both early and long-standing RA and other inflammatory arthritides, prevent radiographic progression, and improve the patients' health-related quality of life. However, they are more effective in combination with methotrexate (MTX) t…

Cartilage Articularmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsImmunologyArthritisPharmacologyArthritis Rheumatoidchemistry.chemical_compoundChondrocytesPharmacotherapyTocilizumabDrug TherapyRheumatoidInternal medicinemedicineHumansImmunology and AllergyArthritis Rheumatoid; Cartilage Articular; Chondrocytes; Drug Therapy Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Inflammation Mediators; Pharmaceutical Preparations; Randomized Controlled Trials as Topic; Tumor Necrosis Factor-alphaAdverse effectRandomized Controlled Trials as TopicTumor Necrosis Factor-alphabusiness.industryArthritisAbataceptmedicine.diseaseClinical trialCartilagePharmaceutical PreparationschemistryRheumatoid arthritisCombinationDrug Therapy CombinationRituximabInflammation MediatorsbusinessArticularmedicine.drugAutoimmunity Reviews
researchProduct

THU0349 A Double-Blind, Randomised, Parallel Group, Active Controlled, Multicentre Study to Assess the Therapeutic Non-Inferiority of Skp-021, A 0.3%…

2014

Background NSAIDs are the first choice for management of acute musculoskeletal pain. Acute musculoskeletal pain is often associated with trauma, surgery, musculoskeletal injuries like strains, sprains and over-use injuries Objectives The primary study endpoint was the estimate of the non-inferiority of the Test drug (Ketoprofen) vs. the Reference drug (Diclofenac). This was performed by assessment of the proportion of responders (response: 50% or more reduction of baseline VAS % (95%CI) at the end of treatment) in the two treatment groups. Methods This phase III, randomised, blinded, active-control and non-inferiority study involved 697 adults with acute muskuloskeletal pain. Participants w…

Ketoprofenmedicine.medical_specialtyActivities of daily livingbusiness.industryImmunologyDiclofenac SodiumGeneral Biochemistry Genetics and Molecular BiologyDouble blindTendernessDiclofenacNon inferiorityRheumatologymedicinePhysical therapyImmunology and AllergyIn patientmedicine.symptombusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia Registry

2022

ObjectiveFibromyalgia (FM) is a chronic musculoskeletal pain syndrome of unknown aetiopathogenesis. Its development and maintenance are related to the interplay of biological, psychological, and contextual factors. Among the contextual factors, sociodemographic aspects are poorly elucidated. This study aimed to evaluate the relationships between sociodemographic/ clinical factors and symptom severity measures using a web-based registry of patients with FM.MethodsAdult patients with an ACR 2010/2011 diagnosis of FM underwent a clinical evaluation and were asked to complete questionnaires covering their sociodemographic data (gender, age, marital status, educational level), and disease-specif…

AdultMalesociodemographic factorsImmunologyReproducibility of ResultsSeverity of Illness IndexRheumatologysociodemographic factors.Surveys and QuestionnairesQuality of LifegenderImmunology and AllergyHumansFemalefibromyalgiaRegistriesChronic Painadult; female; humans; male; quality of life; registries; reproducibility of results; severity of illness index; sociodemographic factors; surveys and questionnaires; chronic pain; fibromyalgia
researchProduct

Lack of association of the -463 G/A myeloperoxidase promoter polymorphism with Behcet's disease in Italian patients.

2007

Objective. To investigate potential associations between the � 463G/A myeloperoxidase (MPO) promoter polymorphism and susceptibility to, and clinical expression of, Behcet's disease (BD). Methods. One hundred and seventy-five Italian patients who satisfied the International Study Group criteria for BD and 235 healthy age- and sex-matched blood donors were genotyped for the �463G/A promoter polymorphism of the MPO gene by molecular methods. The patients were subgrouped according to the presence or absence of clinical manifestations. Results. The distribution of allele and genotype frequencies of the MPO �463A/G polymorphism did not differ significantly between the BD patients and the healthy…

AdultMalemedicine.medical_specialtySystemic diseaseAdult; Behcet Syndrome; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; Histocompatibility Testing; Humans; Male; Peroxidase; Promoter Regions Genetic; Polymorphism GeneticHeterozygoteGenotypeBehcet's diseaseBehçet's disease; Disease manifestation; Myeloperoxidase; Myeloperoxidase gene polymorphism; Adult; Behcet Syndrome; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; Histocompatibility Testing; Humans; Male; Peroxidase; Promoter Regions Genetic; Polymorphism Genetic; Rheumatology; Pharmacology (medical)Promoter RegionsRheumatologyGeneticGene FrequencyInternal medicineGenotypemedicineHumansPharmacology (medical)Genetic Predisposition to DiseaseAllelePolymorphismPromoter Regions GeneticPeroxidasePolymorphism Geneticbiologybusiness.industryBehcet SyndromeHistocompatibility TestingOdds ratiomedicine.diseaseRheumatologyGenotype frequencyMyeloperoxidaseImmunologybiology.proteinFemalebusinessRheumatology (Oxford, England)
researchProduct

Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases

2017

Background The expression of CD70 on T cells is greatly enhanced by antigen-presenting cell (APC)-associated signals, such as tumour necrosis factor(TNF)-α, which is constitutionally high in patients with inflammatory bowel disease (IBD). Experimentally, the chronic activation of CD27 as a result of the constitutive expression of CD70 leads to the demise of B cells in bone marrow (BM) and the secondary lymphoid organs. The aim of this study was to assess the number and phenotype of circulating B cell in untreated IBD patients and their counterparts treated with biological anti-TNF drugs. Methods The study involved 13 untreated IBD patients, 36 IBD patients treated with biological drugs, and…

Male0301 basic medicineT-LymphocytesImmunophenotypingB cell homeostasisBiological drugs; Inflammatory bowel diseases; Plasmablasts; TNF-αHomeostasisImmunology and AllergyCD20B-LymphocytesbiologyB-LymphocyteAntibodies MonoclonalMiddle AgedFlow Cytometrymedicine.anatomical_structureFemaleTumor necrosis factor alphaImmunotherapyAntibodyPlasmablastsHumanAdultAdolescentBiological drugImmunologyB-Lymphocyte SubsetsPlasmablastCD19ImmunophenotypingYoung Adult03 medical and health sciencesHomeostasimedicineHumansBiological drugsB cellB-Lymphocyte SubsetPharmacologyTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseInflammatory Bowel Diseases030104 developmental biologyT-LymphocyteTNF-αImmunologybiology.proteinBone marrowbusinessCD27 LigandInternational Immunopharmacology
researchProduct

B lymphocyte intestinal homing in inflammatory bowel disease.

2011

Abstract Background Inflammatory bowel disease (IBD) is thought to be due to an abnormal interaction between the host immune system and commensal microflora. Within the intestinal immune system, B cells produce physiologically natural antibodies but pathologically atypical anti-neutrophil antibodies (xANCAs) are frequently observed in patients with IBD. The objective is to investigate the localisation of immunoglobulin-producing cells (IPCs) in samples of inflamed intestinal tissue taken from patients with IBD, and their possible relationship with clinical features. Methods The IPCs in small intestinal, colonic and rectal biopsy specimens of patients with IBD were analysed by means of immun…

lcsh:Immunologic diseases. AllergylymphocytesAdultMalePathologymedicine.medical_specialtyLymphocyteBiopsyImmunologyFluorescent Antibody TechniqueInflammatory bowel diseaseImmunophenotypingImmunomodulationImmune systemAntigens CDCell Movementinflammatory bowel diseasemedicineHumansB1 cells; Inflammation; Inflammatory bowel disease; Lymphocyte homing; Lymphocytes; Mucosal immunity; Adult; Aged; Antigens CD; B-Lymphocytes; Biopsy; Cell Differentiation; Cell Movement; Female; Fluorescent Antibody Technique; Humans; Immunoglobulin M; Immunomodulation; Immunophenotyping; Inflammatory Bowel Diseases; Intestinal Mucosa; Intestines; Male; Middle Aged; ImmunologyIntestinal MucosaB cellAgedB-LymphocytesbiologyB1 cellsCell DifferentiationMiddle Agedmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisB-1 cellIntestinesmedicine.anatomical_structureImmunoglobulin MinflammationImmunologybiology.proteinmucosal immunityFemalelymphocyte homingCD5Antibodylcsh:RC581-607Research Article
researchProduct

The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients

2021

Abstract Objective Various studies have shown that overweight and obesity are central features of FM, but the real impact of a high BMI on clinical severity in patients with FM is still controversial. The aim of this study was to analyse the relationships between BMI categories and measures of symptom severity and functional impairment using data from a Web-based registry of patients with FM. Methods Adult patients with an ACR 2010/2011 diagnosis of FM underwent a complete physical examination and laboratory tests and were asked to complete a package of questionnaires covering their sociodemographic and treatment details, in addition to the following disease-specific questionnaires: the rev…

medicine.medical_specialtyobesityCross-sectional studyRevised Fibromyalgia Impact QuestionnaireOverweightNO03 medical and health sciencesBMI0302 clinical medicineRheumatologyInternal medicineFibromyalgiamedicineLS4_5030212 general & internal medicine030203 arthritis & rheumatologybusiness.industrymedicine.diseaseObesityDistressclinical severitywidespread painOriginal ArticlefibromyalgiaUnderweightmedicine.symptomAcademicSubjects/MED00010businessBody mass indexBMI; clinical severity; fibromyalgia; obesity; widespread pain
researchProduct

AB0427 Clinical and laboratory findings in patients with late-onset sle and correlations with il6 concentrations

2013

Background Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease that usually develops in women aged 18-50 years. It is known that age at onset modifies the clinical manifestations of SLE, and so the elderly may form a specific patient subgroup. It is now well established that the serum levels of the cytokines interleukin (IL) 6 and IL10 are increased in patients with SLE (1). Objectives The primary aim was to compare the type of clinical involvement and autoantibodies in patients with late-onset (LO) or early-onset (EO) SLE. The second aim was to compare IL6 levels in the two patient groups and their possible correlations with clinical and immunological manifestations. Meth…

medicine.medical_specialtySystemic lupus erythematosusAnti-nuclear antibodybusiness.industryImmunologyAutoantibodyArthritismedicine.diseaseGastroenterologyGeneral Biochemistry Genetics and Molecular BiologyRheumatologyRheumatologyimmune system diseasesInternal medicineImmunologymedicineImmunology and AllergyAge of onsetmedicine.symptomskin and connective tissue diseasesMalar rashbusinessSerositisAnnals of the Rheumatic Diseases
researchProduct

Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis

2013

Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and a significant cause of morbidity and mortality. Usual interstitial pneumonia and nonspecific interstitial pneumonia seem to be the most frequent patterns in RA patients with ILD, although the proportion of patients with usual interstitial pneumonia is higher than among patients with other systemic rheumatic autoimmune diseases. RA patients with ILD most frequently present with chronic symptoms of cough and dyspnea when climbing stairs or walking uphill. A physical examination may reveal inhalatory crackles and a pulmonary function test demonstrates restrictive physiology, often with re…

medicine.medical_specialtyImmunologyArthritisLung biopsyGastroenterologyPulmonary function testingArthritis RheumatoidAntibodies Monoclonal Murine-DerivedPatient Education as TopicUsual interstitial pneumoniaInternal medicinemedicineHumansImmunology and AllergyAntibodies BlockingPneumonitisLeflunomideClinical Trials as TopicTumor Necrosis Factor-alphabusiness.industryInterstitial lung diseaseIsoxazolesmedicine.diseaserespiratory tract diseasesMethotrexateAntirheumatic AgentsRheumatoid arthritisImmunologyLung Diseases InterstitialRituximabbusinessLeflunomidemedicine.drugExpert Review of Clinical Immunology
researchProduct

Unusual B cell morphology in inflammatory bowel disease.

2012

B lymphocytes express various different types of surface immunoglobulins that are largely unrelated to other hematological lines, although some reports have described a relationship between malignant B cells and other cells such as macrophages. Multiple genes of hematopoietic lineage, including transcription factors, are co-expressed in hematopoietic stem cells and progenitors, a phenomenon referred to as "lineage priming". Changes in the expression levels and timing of transcription factors can induce the lineage conversion of committed cells, which indicates that the regulation of transcription factors might be particularly critical for maintaining hierarchical hematopoietic development. …

MalePathologyCD79BiopsyUlcerativeSmallInflammatory bowel diseaseInflammatory bowel diseaseMucosal immunityCrohn DiseaseIntestine SmallLymphocytesMicroscopyB-Lymphocytesmedicine.diagnostic_testMiddle AgedColitisFucosyltransferasesIntestineSurfaceHaematopoiesismedicine.anatomical_structureAntigens SurfaceFemaleStem cellB-1 B cellsAdultmedicine.medical_specialtyLymphocyte homingColonLewis X AntigenBiologyFluorescencePathology and Forensic MedicineAntigeninflammatory bowel diseaseBiopsymedicineHumansCell LineageProgenitor cellAntigensB cellInflammatory bowel disease; Inflammation; Mucosal immunity; Lymphocytes; B-1 B cells; Lymphocyte homing; CD15+cells; Adult; Antigens Surface; B-Lymphocytes; Biomarkers; Biopsy; Cell Lineage; Cell Nucleus; Colitis Ulcerative; Colon; Crohn Disease; Female; Fucosyltransferases; Humans; Immunoglobulin M; Inflammatory Bowel Diseases; Intestine Small; Lewis X Antigen; Male; Microscopy Fluorescence; Middle Aged; RectumInflammationCell NucleusRectumCell Biologymedicine.diseaseInflammatory Bowel DiseasesImmunoglobulin MMicroscopy FluorescenceImmunologyColitis UlcerativeCD15+cellsBiomarkersPathology, research and practice
researchProduct

Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases

2018

The risk of cardiovascular (CV) events and mortality is significantly higher in patients with systemic rheumatic diseases than in the general population. Although CV involvement in such patients is highly heterogeneous and may affect various structures of the heart, it can now be diagnosed earlier and promptly treated. Various types of assessments are employed for the evaluation of CV risk such as transthoracic or transesophageal echocardiography, magnetic resonance imaging (MRI), and computed tomography (CT) to investigate valve abnormalities, pericardial disease, and ventricular wall motion defects. The diameter of coronary arteries can be assessed using invasive quantitative coronarograp…

medicine.medical_specialtyPopulationSpeckle tracking echocardiographyReview030204 cardiovascular system & hematologyendothelial dysfunction03 medical and health sciences0302 clinical medicinemedicine.arteryInternal medicineIntravascular ultrasoundmedicinesystemic rheumatic diseasesBrachial arteryeducationatherosclerosis; computed tomography; coronary artery diseases; endothelial dysfunction; plasma asymmetric dimethylarginine; systemic rheumatic diseases030203 arthritis & rheumatologyeducation.field_of_studylcsh:R5-920medicine.diagnostic_testbusiness.industryCoronary flow reserveMagnetic resonance imagingcomputed tomographyGeneral Medicineplasma asymmetric dimethylarginineCoronary arteriescoronary artery diseasesmedicine.anatomical_structurePositron emission tomographyCardiologyMedicineatherosclerosisbusinesslcsh:Medicine (General)Frontiers in Medicine
researchProduct

THU0164 Subclinical atherosclerosis and cardiovascular events in italian patients with rheumatoid arthritis: results from multicenter girrcs (gruppo …

2017

Background Several studies showed a close relationship between Rheumatoid Arthritis (RA) and accelerated atherosclerosis [1,2]. At the best of our knowledge, no such study has been carried out in a large Italian series. Objectives To investigate the prevalence of presence of subclinical atherosclerosis and history of cardio-cerebrovascular events (CVEs), in 1266 patients consecutively admitted to Rheumatology Units throughout the whole Italy. Methods From 01/01/2015 to 31/12/2015, 1266 consecutive patients admitted to GIRRCS centres, satisfying ACR/EULAR criteria for RA were investigated for: i. traditional cardiovascular risk factors: gender, age, smoking habit, cholesterol, triglycerides,…

030203 arthritis & rheumatology0301 basic medicinemedicine.medical_specialtybusiness.industryType 2 diabetesmedicine.diseaseRheumatologySurgery03 medical and health sciences030104 developmental biology0302 clinical medicineRheumatoid arthritisInternal medicineHeart failuremedicineMyocardial infarctionMetabolic syndromebusinessStrokeSubclinical infection
researchProduct

Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multi…

2017

Supplemental Digital Content is available in the text

Blood GlucoseMalerheumatoid arthritisCross-sectional studyType 2 diabetesTriglycerideArthritis Rheumatoid0302 clinical medicineRisk FactorsCardiovascular DiseasePrevalence030212 general & internal medicineMyocardial infarctionStrokeSubclinical infectionAged 80 and overMetabolic SyndromeMetabolic Syndrome XGeneral MedicineMiddle Agedinflammatory processCholesterolItalyCardiovascular DiseasesRheumatoid arthritisAtherosclerosiHypertensionComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemaleHumanResearch ArticleAdultmedicine.medical_specialtyAdolescentsubclinical atherosclerosisObservational Study03 medical and health sciencesYoung Adultcardiovascular eventsInternal medicinemedicineHumansTriglyceridesAged030203 arthritis & rheumatologyCross-Sectional Studiebusiness.industryRisk Factor6900medicine.diseaseAtherosclerosisCross-Sectional StudiesDiabetes Mellitus Type 2Physical therapyMetabolic syndromebusinessRheumatismtraditional cardiovascular risk factorMedicine
researchProduct

Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database

2021

ObjectiveThe role of age in influencing the severity of fibromyalgia (FM) is still controversial. The aim of this study is to define the contribution of age in the severity of FM from data from a large national database.MethodsThis cross-sectional study included adult patients with FM diagnosed according to the 2010/2011 American College of Rheumatology criteria. Disease severity was assessed with the revised Fibromyalgia Impact Questionnaire (FIQR) and the modified Fibromyalgia Assessment Status (FAS 2019mod). Patients were grouped into five age categories (between 18-40 years, between 41- 50 years, between 51-60 years, between 61-70 years, and =71 years). Differences in disease severity b…

AdultMaleSettore MED/16 - REUMATOLOGIAAdolescentImmunologyReproducibility of ResultsMiddle AgedFAS 2019mod.Severity of Illness IndexYoung AdultCross-Sectional StudiesRheumatologyagenational databaseSurveys and QuestionnairesQuality of LifeImmunology and AllergyHumansdisease severityFemalefibromyalgiaFIQR
researchProduct

AB0465 Etanercept therapy in rheumatoid arthritis patients with moderate or severe disease activity

2013

Background Rheumatoid arthritis (RA) is conventionally defined as moderate when the disease activity score assessed in 28 joints (DAS28) is ≥3.2, and high disease with DAS28 >5.1 Objectives Aim of this analysis was to evaluate the rate of remission and LDA (low disease activity), in RA patients starting etanercept therapy with moderate disease activity in the real world settings Methods The clinical records were retrospectively analysed from the Italian nationwide registry, called GISEA (Gruppo Italiano Studio Early Arthritis). RA patients with moderate (Mod-RA) and high (H-RA) disease activity (DAS28 >3.2) with incomplete response to conventional DMARDs and beginning a treatment with etane…

musculoskeletal diseasesModerate to severemedicine.medical_specialtybusiness.industryImmunologySevere diseaseDiseasemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyEtanerceptSurgeryRheumatologyStandard careRheumatoid arthritisInternal medicineImmunology and AllergyMedicineEtanercept therapybusinessEarly arthritismedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients

2021

Abstract Objective To establish optimal cut-off values for the scores of the revised Fibromyalgia Impact Questionnaire (FIQR), the modified Fibromialgia Assessment Scale (FAS 2019mod), and the Polysymptomatic Distress Scale (PDS) in order to distinguish five levels of FM disease severity. Methods Consecutive FM patients were evaluated with the three clinimetric indices, and each patient was required to answer the anchor question: ‘In general, would you say your health is 1 = very good, 2 = good, 3 = fair, 4 = poor, or 5 = very poor?’—which represented the external criterion. Cut-off points were established through the interquartile reconciliation approach. Results The study sample consisted…

MalePercentileSettore MED/16 - REUMATOLOGIAFibromyalgiaCross-sectional studyseverityDiseaseSeverity of Illness IndexEconomica0302 clinical medicinemodifiedInterquartile rangeRetrospective StudieFibromyalgiaSurveys and QuestionnairesSurveys and QuestionnairePharmacology (medical)030212 general & internal medicinecut-off pointsPain MeasurementFibromyalgia Assessment Status; cut-off points; fibromyalgia; modified; polysymptomatic distress scale; revised Fibromyalgia Impact Questionnaire; severity; Cross-Sectional Studies; Female; Fibromyalgia; Follow-Up Studies; Humans; Incidence; Italy; Male; Middle Aged; Pain Measurement; Prognosis; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Quality of LifeIncidencerevised Fibromyalgia Impact Questionnairecut-off points; fibromyalgia; Fibromyalgia Assessment Status; modified; polysymptomatic distress scale; revised Fibromyalgia Impact Questionnaire; severityMiddle AgedPrognosisDistressItalyFemalefibromyalgiaFibromyalgia Assessment StatusHumanmedicine.medical_specialtyPrognosiRevised Fibromyalgia Impact QuestionnaireFollow-Up Studie03 medical and health sciencesRheumatologyInternal medicineSeverity of illnesscut-off pointmedicineHumansRetrospective Studies030203 arthritis & rheumatologyCross-Sectional Studiebusiness.industrymedicine.diseaseFibromyalgia Assessment StatuCross-Sectional StudiesFibromyalgia; severity; cut-off points; revised Fibromyalgia Impact Questionnaire; modified; Fibromyalgia Assessment Status; polysymptomatic distress scalepolysymptomatic distress scalefibromyalgia assessment status; cut-off points; fibromyalgia; modified; polysymptomatic distress scale; revised fibromyalgia impact questionnaire; severityQuality of LifebusinessFollow-Up Studies
researchProduct

Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey

2016

Background The aim was to establish how patients experience the impact of spondyloarthritis (SpA) on work disability and working life. Methods The survey was performed in 17/20 regions in Italy (1 January to 31 March 2013). A multiple-choice questionnaire was published on the official website of the sponsor - the National Association of Rheumatic Patients (ANMAR) - and hard-copies were distributed at outpatient clinics for rheumatic patients. Results Respondents (n = 770) were of both sexes (56 % men), educated (62 % at high school or more), of working age (75 % aged ≤60 years), and affected by SpA. The most common types diagnosed were ankylosing spondylitis (AS) (39 %) and psoriatic arthri…

MaleAbsenteeism; Presenteeism; Spondyloarthritis; Survey; WPI; Adult; Aged; Arthritis Psoriatic; Employment; Female; Humans; Italy; Male; Middle Aged; Self Report; Spondylitis Ankylosing; Surveys and Questionnaires; Absenteeism; Disability Evaluation; Quality of Life; Rheumatology; Immunology and Allergy; ImmunologySettore MED/16 - REUMATOLOGIAWPIAlternative medicinePsoriaticDisability Evaluation0302 clinical medicineSurveys and QuestionnairesAbsenteeismSurveys and QuestionnaireImmunology and Allergy030212 general & internal medicineSurveyAbsenteeism; Presenteeism; Spondyloarthritis; Survey; WPIWorking lifeWork disabilityMiddle AgedSpondyloarthritis Survey Absenteeism Presenteeism WPIItalyAbsenteeismFemaleResearch ArticleHumanAdultEmploymentAnkylosingmusculoskeletal diseasesmedicine.medical_specialtyImmunology03 medical and health sciencesQuality of life (healthcare)RheumatologySpondyloarthritismedicineHumansSpondylitis AnkylosingSelf reportAged030203 arthritis & rheumatologyAbsenteeism; Presenteeism; Spondyloarthritis; Survey; WPI; Adult; Aged; Arthritis Psoriatic; Employment; Female; Humans; Italy; Male; Middle Aged; Self Report; Spondylitis Ankylosing; Surveys and Questionnaires; Absenteeism; Disability Evaluation; Quality of Life; Immunology and Allergy; Rheumatology; Immunologybusiness.industryArthritisArthritis PsoriaticPresenteeismAbsenteeism; Presenteeism; Spondyloarthritis; Survey; WPI; Rheumatology; Immunology; Immunology and AllergyFamily medicinePresenteeismQuality of LifeSelf ReportSpondyloarthritibusinessSpondylitisArthritis Research & Therapy
researchProduct

Clinical manifestations of Behçet's disease in 137 Italian patients: Results of a multicenter study

2005

Objective. To determine the type and frequency of clinical features of Behcets disease in a population of Italian patients. Methods. We retrospectively v studied 137 Italian patients (76 males and 61 females, age at onset 29.6 +/- 12.2 [mean +/-SD] Years) seen consecutively in nine different referral centers. The duration of follow-up (it study entry was 10.9 +/- 8.2 years. Virtually all patients fulfilled the classification criteria developed by the International Study Group for Behcets disease. The clinical manifestations of the patients were recorded by the attending physicians using specifically designed forms. \ Results. The most frequent manifestations at disease onset were oral (78.3…

AdultMaleUveitisStomatitisItalyBehcet Syndromesigns and symptomHumansStomatitis AphthousFemaleAphthousAdult; Behcet Syndrome; Female; Humans; Italy; Male; Retrospective Studies; Stomatitis Aphthous; UveitisRetrospective Studies
researchProduct

Significance of serum Il-9 levels in inflammatory bowel disease

2015

IL-9, which may be an inflammatory or regulatory cytokine, can be experimentally produced in a Th17 or modified Th2 context in the presence of T cell receptor (TCR) stimulation. The primary aim of this study was to measure serum IL-9 levels in patients with inflammatory bowel disease (IBD), and evaluate their relationships with the patients’ clinical characteristics. The secondary aim was to determine the levels of interferon-γ (IFN (interferon)-γ), Th2 cytokines (IL-4, IL-5 and IL-13), and IL-6 in order to clarify the context of detectable peripheral cytokines in which IL-9 is produced. Venous blood samples of 43 IBD patients (20 with Crohn’s disease [CD] and 23 with ulcerative colitis [U…

AdultMaleAdolescentmedicine.medical_treatmentImmunologyPopulationContext (language use)lymphocyteInflammatory bowel diseaseTh17 CellTh2 CellsmedicineImmunology and AllergyHumansInterleukin 9educationInterleukin 6Pharmacologyeducation.field_of_studybiologyinflammation; inflammatory bowel disease; interleukin; lymphocyte homing; lymphocytes; mucosal immunity; Adolescent; Adult; Female; Humans; Inflammatory Bowel Diseases; Interleukin-6; Interleukin-9; Male; Middle Aged; Th17 Cells; Th2 Cells; Immunology and Allergy; Immunology; Pharmacologybusiness.industryinterleukinInterleukin-6Inflammatory Bowel DiseaseInterleukin-9Middle Agedmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisCytokineinflammationImmunologybiology.proteinTh17 Cellsmucosal immunityFemalelymphocyte homingAntibodybusinessHuman
researchProduct

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (r…

2017

Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified. Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians. After a systematic review of the literature, the results and the discussions from each working group were summarised in different statements. Due to th…

0301 basic medicineQuality managementEffectivenesslaw.inventionSystemic sclerosi0302 clinical medicineAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Immunology and Allergy; ImmunologylawAntiphospholipid syndromeImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSSpondyloarthritideClinical Trials as TopicEffectiveneDisease ManagementQuality Improvement3. Good healthSjogren's syndromeRheumatoid arthritis[SDV.IMM]Life Sciences [q-bio]/ImmunologySystemic sclerosisUnmet needmedicine.medical_specialtyRemissionImmunologyAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs;Systemic lupus erythematosuUnmet needs; rheumatoid arthritis; spondyloarthritides;Unmet needsNOAutoimmune Diseases03 medical and health sciencesSystemic lupus erythematosusAntiphospholipid syndromeInternal medicineRheumatic DiseasesmedicineHumansRheumatoid arthritisIntensive care medicineRheumatoid arthriti030203 arthritis & rheumatologyAutoimmune diseasetherapybusiness.industryAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Autoimmune Diseases; Clinical Trials as Topic; Disease Management; Humans; Quality Improvement; Rheumatic Diseases; Immunology and Allergy; Immunologymedicine.diseaseRheumatologyBiologic drugs treatment030104 developmental biologyautoimmune rheumatic diseasesPhysical therapyCLARITYSpondyloarthritidesbusinessWorking group
researchProduct

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register

2014

Abstract Introduction Rituximab (RTX) is a monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) in association with methotrexate (MTX). Objectives To evaluate the efficacy and safety of RTX–MTX combination therapy compared with RTX alone in the treatment of RA. Methods We analyzed data from a prospective cohort study, the Italian biologic register GISEA, to investigate the efficacy and safety of rituximab. Moreover, the adverse events (AE) and the causes of discontinuation therapy were analyzed. Results We identified 338 RA patients, 162 treated with RTX and 176 with RTX–MTX. After 52 and 104 weeks of therapy the disease activity score in 28 joints and the H…

RegistrieMaleanti-CD20 rituximab; rheumatoid arthritis; GISEArheumatoid arthritisSettore MED/16 - REUMATOLOGIAAnti-CD20Arthritis RheumatoidAntibodies Monoclonal Murine-DerivedRheumatoidMonoclonalRegistriesProspective cohort studyGISEAAnti-CD20; Methotrexate; Rheumatoid arthritis; Rituximab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Murine-Derived; Antirheumatic Agents; Arthritis Rheumatoid; Drug Therapy Combination; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome; RegistriesAntirheumatic AgentAntibodies MonoclonalMiddle AgedTreatment OutcomeRituximab rheumatoid arthritisAntirheumatic AgentsRheumatoid arthritisCombinationMonoclonalDrug Therapy CombinationFemaleRituximabRituximabHumanmedicine.drugmusculoskeletal diseasesAdultMurine-Derivedmedicine.medical_specialtyCombination therapyAntibodiesNOAnti-CD20; Methotrexate; Rheumatoid arthritis; RituximabDrug TherapyRheumatologyanti-CD20 rituximabInternal medicinemedicineHumansRheumatoid arthritisAdverse effectRheumatoid arthritiAnti-CD20; Methotrexate; Rheumatoid arthritis; Rituximab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Murine-Derived; Antirheumatic Agents; Arthritis Rheumatoid; Drug Therapy Combination; Female; Humans; Male; Methotrexate; Middle Aged; Rituximab; Treatment Outcome; Registries; RheumatologyAgedbusiness.industryArthritismedicine.diseaseSurgeryDiscontinuationMethotrexateMethotrexatebusinessJoint Bone Spine
researchProduct

Morphological distribution of μ chains and cd15 receptors in colorectal polyp and adenocarcinoma specimens

2013

BACKGROUND: We have recently investigated the localisation of immunoglobulin-producing cells (IPCs) in inflamed intestinal tissue samples from patients with inflammatory bowel disease (IBD), and identified two main patterns of B lymphocyte infiltration: one characterised by the moderate strong stromal localisation of small B1 cell-like IgM+/CD79+/CD20-/CD21-/CD23-/CD5 ± IPCs, and the other by the peri-glandular localisation of IPCs with irregular nuclei that had surface markers specific for a B cell subset (IgM and CD79), but quantitative differences in their λ and κ chains. The same patients were also tested for CD15+ receptors, which were localised on inflammatory cell surfaces or in the …

Sialyl-LewisXPathologymedicine.medical_specialtyHistologyStromal cellCD792734B-1 cells; Colorectal adenocarcinoma; Inflammatory bowel disease; Matrix metalloproteinases; Sialyl-LewisX; 2734; HistologyCell morphologyImmunofluorescencecolorectal polyp and adenocarcinomaInflammatory bowel diseaseColorectal adenocarcinomaPathology and Forensic MedicineB-1 cellsmedicineReceptorB cellImmunoperoxidasemedicine.diagnostic_testbusiness.industrymedicine.diseaseMatrix metalloproteinasesmedicine.anatomical_structureAdenocarcinomabusinessResearch ArticleBMC Clinical Pathology
researchProduct

Additional file 1: of Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey

2016

Anonymous questionnaire (multiple choice questions). (PDF 56 kb)

researchProduct

Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Regist…

2012

Objective.To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid arthritis (RA), as derived from an Italian national registry.Methods.The clinical records of 853 adult patients with RA in the GISEA (Gruppo Italiano Studio Early Arthritis) registry were prospectively analyzed to compare drug survival rates and the baseline factors that may predict adherence to therapy.Results.In 2003 and 2004, 324 patients started treatment with adalimumab, 311 with etanercept, and 218 with infliximab. After 4 years, the global retention rate of anti-TNF-α therapy was 42%. Etanercept survival (51.4%) …

MaleTime FactorsHealth StatusArthritisKaplan-Meier EstimateReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptArthritis RheumatoidRandomized controlled triallawRheumatoidMonoclonalReceptorsImmunology and AllergyProspective StudiesRegistriesskin and connective tissue diseasesProspective cohort studyHumanizedAntibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biological Markers; Drug Substitution; Female; Health Status; Humans; Immunoglobulin G; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesPain MeasurementDrug SubstitutionAntibodies MonoclonalMiddle AgedArthralgiaAdalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesSurvival RateItalyRheumatoid arthritisAntirheumatic AgentsBiological MarkersAdalimumab; Drug survival; Etanercept; Infliximab; Adalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; Registries; Rheumatology; Immunology; Immunology and AllergyFemalemedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyImmunologyAntibodies Monoclonal HumanizedAntibodiesRheumatologyDrug survivalInternal medicineAdalimumabmedicineHumansSurvival ratebusiness.industryTumor Necrosis Factor-alphaArthritisAdalimumabmedicine.diseaseInfliximabInfliximabSurgeryImmunoglobulin GJointsbusinessTumor Necrosis FactorBiomarkers
researchProduct